View in EDS HTML Full Text PDF Full Text

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Saved in:
Bibliographic Details
Title: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
Authors: Parmar G; Illawarra Cancer Care Centre, Wollongong Hospital, University of Wollongong, Wollongong, NSW, Australia. gurdeep.parmar@health.nsw.gov.au., Capra M; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil., Seguro F; Hematologia e Hemoterapia do Hospital das Clinicas - FMUSP, São Paulo, Brazil., Hungria V; Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea., Delimpasi S; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos General Hospital, Athens, Greece., Minařík J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic., Špička I; Departments of Medicine and Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Pour L; Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic., Marques H; Department of Hematology, Hospital de Braga, Academic Clinical Center of Braga, Braga, and CINTESIS, Oporto University, Braga, Portugal., Esteves G; Hospital de Santa Maria, Centro de Investigação Clínica, Lisboa, Portugal., Sunami K; Department of Hematology, NHO Okayama Medical Center, Okayama, Japan., Yuda J; Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Hájek R; Department of Haemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Mihályová J; Department of Haemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Soufflet C; Sanofi Research & Development, Vitry-sur-Seine, France., Yu D; Sanofi Research & Development, Cambridge, MA, USA., Benlhassan K; Excelya on Behalf of Sanofi Research & Development, Vitry-sur-Seine, France., Koch V; Excelya on Behalf of Sanofi Research & Development, Vitry-sur-Seine, France., Comerford E; Sanofi Research & Development, Cambridge, MA, USA., Cordero P; Sanofi Research & Development, Reading, UK., Suzan F; Sanofi Research & Development, Vitry-sur-Seine, France., Quach H; Clinical Haematology Service, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
Source: Blood cancer journal [Blood Cancer J] 2025 Dec 27; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2025 Dec 27.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41455697
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Parmar+G%22">Parmar G</searchLink>; Illawarra Cancer Care Centre, Wollongong Hospital, University of Wollongong, Wollongong, NSW, Australia. gurdeep.parmar@health.nsw.gov.au.<br /><searchLink fieldCode="AU" term="%22Capra+M%22">Capra M</searchLink>; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Seguro+F%22">Seguro F</searchLink>; Hematologia e Hemoterapia do Hospital das Clinicas - FMUSP, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Hungria+V%22">Hungria V</searchLink>; Department of Hematology and Oncology, Clínica São Germano, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Department of Medicine, Korea University, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos General Hospital, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Minařík+J%22">Minařík J</searchLink>; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Špička+I%22">Špička I</searchLink>; Departments of Medicine and Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Pour+L%22">Pour L</searchLink>; Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Marques+H%22">Marques H</searchLink>; Department of Hematology, Hospital de Braga, Academic Clinical Center of Braga, Braga, and CINTESIS, Oporto University, Braga, Portugal.<br /><searchLink fieldCode="AU" term="%22Esteves+G%22">Esteves G</searchLink>; Hospital de Santa Maria, Centro de Investigação Clínica, Lisboa, Portugal.<br /><searchLink fieldCode="AU" term="%22Sunami+K%22">Sunami K</searchLink>; Department of Hematology, NHO Okayama Medical Center, Okayama, Japan.<br /><searchLink fieldCode="AU" term="%22Yuda+J%22">Yuda J</searchLink>; Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Hájek+R%22">Hájek R</searchLink>; Department of Haemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Mihályová+J%22">Mihályová J</searchLink>; Department of Haemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Soufflet+C%22">Soufflet C</searchLink>; Sanofi Research & Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Yu+D%22">Yu D</searchLink>; Sanofi Research & Development, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Benlhassan+K%22">Benlhassan K</searchLink>; Excelya on Behalf of Sanofi Research & Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Koch+V%22">Koch V</searchLink>; Excelya on Behalf of Sanofi Research & Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Comerford+E%22">Comerford E</searchLink>; Sanofi Research & Development, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Cordero+P%22">Cordero P</searchLink>; Sanofi Research & Development, Reading, UK.<br /><searchLink fieldCode="AU" term="%22Suzan+F%22">Suzan F</searchLink>; Sanofi Research & Development, Vitry-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Quach+H%22">Quach H</searchLink>; Clinical Haematology Service, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2025 Dec 27; Vol. 16 (1), pp. 16. <i>Date of Electronic Publication: </i>2025 Dec 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41455697
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-025-01436-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 16
    Titles:
      – TitleFull: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Parmar G
      – PersonEntity:
          Name:
            NameFull: Capra M
      – PersonEntity:
          Name:
            NameFull: Seguro F
      – PersonEntity:
          Name:
            NameFull: Hungria V
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Delimpasi S
      – PersonEntity:
          Name:
            NameFull: Minařík J
      – PersonEntity:
          Name:
            NameFull: Špička I
      – PersonEntity:
          Name:
            NameFull: Pour L
      – PersonEntity:
          Name:
            NameFull: Marques H
      – PersonEntity:
          Name:
            NameFull: Esteves G
      – PersonEntity:
          Name:
            NameFull: Sunami K
      – PersonEntity:
          Name:
            NameFull: Yuda J
      – PersonEntity:
          Name:
            NameFull: Hájek R
      – PersonEntity:
          Name:
            NameFull: Mihályová J
      – PersonEntity:
          Name:
            NameFull: Soufflet C
      – PersonEntity:
          Name:
            NameFull: Yu D
      – PersonEntity:
          Name:
            NameFull: Benlhassan K
      – PersonEntity:
          Name:
            NameFull: Koch V
      – PersonEntity:
          Name:
            NameFull: Comerford E
      – PersonEntity:
          Name:
            NameFull: Cordero P
      – PersonEntity:
          Name:
            NameFull: Suzan F
      – PersonEntity:
          Name:
            NameFull: Quach H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 12
              Text: 2025 Dec 27
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1